Ticker Details
Summit Therapeutics Inc. Common Stock Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.
IPO Date:	April 1, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$14.97B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.28 | 3.78%
Avg Daily Range (30 D):	$0.49 | 2.91%
Avg Daily Range (90 D):	$0.45 | 2.65%

Institutional Daily Volume
Avg Daily Volume:	1M
Avg Daily Volume (30 D):	2.06M
Avg Daily Volume (90 D):	2.19M

Trade Size
Avg Trade Size (Sh.):	131
Avg Trade Size (Sh.) (30 D):	70
Avg Trade Size (Sh.) (90 D):	75

Institutional Trades
Total Institutional Trades:	1,517
Avg Institutional Trade:	$3.21M
Avg Institutional Trade (30 D):	$3.39M
Avg Institutional Trade (90 D):	$3.32M
Avg Institutional Trade Volume:	.21M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.51M
Avg Closing Trade (30 D):	$5.91M
Avg Closing Trade (90 D):	$5.6M
Avg Closing Volume:	375.73K

News

Mar 25, 2026 @ 9:24 PM Prediction: 2 Stocks That Will Be Worth More Than ... Source: Prosper Junior Bakiny

Jan 29, 2026 @ 5:28 PM FDA Accepts Summit's Lung Cancer Drug Application,... Source: Vandana Singh

Jan 18, 2026 @ 5:31 PM Trip.com, Regencell Bioscience, And Atlassian Are ... Source: Nabaparna Bhattacharya

Jan 6, 2026 @ 10:12 PM Stock Market Today, Jan. 6: Alumis Shares Surge on... Source: Howard Smith

Dec 5, 2025 @ 6:05 PM Trading Near Its 52-Week Low, Is Summit Therapeuti... Source: David Jagielski

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.44	$-.28	$-1.44
Diluted EPS	$-1.44	$-.28	$-1.44
Revenue
Gross Profit
Net Income / Loss	$-1079.59M	$-219.17M	$-1079.59M
Operating Income / Loss
Cost of Revenue
Net Cash Flow	$120.29M	$-13.27M	$120.29M
PE Ratio